Показано 0 из 0
Дата |
---|
12.04.2024 |
11.04.2024 |
10.04.2024 |
09.04.2024 |
08.04.2024 |
05.04.2024 |
03.04.2024 |
29.03.2024 |
28.03.2024 |
27.03.2024 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
---|---|---|---|---|---|---|---|
|
|
|
|
|
20.08
|
|
|
|
|
|
|
|
|
|
20.08
|
|
|
|
|
|
|
|
|
|
20.08
|
|
|
|
|
|
|
|
|
|
20.08
|
|
|
|
|
|
|
|
|
|
20.08
|
|
|
|
|
|
|
|
|
|
20.08
|
|
|
|
|
|
|
|
|
|
20.08
|
|
|
|
|
|
|
|
|
|
20.08
|
|
|
|
|
|
|
|
|
|
20.08
|
|
|
|
|
|
|
|
|
|
20.08
|
|
|
|
|
Exelixis, Inc. (Exelixis) is a biotechnology company engaged in developing small molecule therapies for the treatment of cancer. The Company is focusing its resources and development efforts on cabozantinib (XL184). It also has a portfolio of other compounds. Cabozantinib is the inhibitor of MET in clinical development and is being evaluated in a development program encompassing multiple cancer indications.